Research cutoff: October 20, 2026. Regulatory status in this area changes on short notice — check the primary FDA and OMB sources linked throughout before relying on any date-sensitive claim.
Key Takeaways
- No FDA rule, guidance document, or drug approval has made BPC-157, TB-500, MOTS-C, KPV, Epitalon, or Semax legal to compound as of October 20, 2026.
- FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 23–24, 2026 and is reported by legal and trade press to have recommended six of seven reviewed peptide groups for the 503A Bulks List — against FDA staff's own prior recommendation. FDA has not posted an official transcript or vote tally confirming the exact counts, and one analysis found that every vote in favor came from the committee members with financial ties to peptide-related businesses or clinics [7].
- On October 14, 2026, HHS and FDA submitted an “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94) to the White House Office of Management and Budget for review. It is at the “Notice” stage of Pending EO 12866 Regulatory Review — not published, not final, not law.
- Separately, FDA has stepped up enforcement in 2026 against both research-use-only peptide sellers (warning letters, August 2026) and a licensed compounding pharmacy selling high volumes of compounded GLP-1 products (warning letter, September 2026) — a reminder that “under policy review” and “compliant today” are not the same thing.
What the FDA Actually Did in 2026, in Sequence
FDA did not issue a single “2026 update.” It took a sequence of distinct actions, each carrying different legal weight. The table below lists what's independently verifiable against a primary FDA or OMB source, and flags the one row (July 2026) where the specific vote counts come from press reporting rather than an FDA-posted record.
What Changed, and What the Formal Rules Still Say
What changed: a defined list of peptide substances exited Category 2's “significant safety risk” designation (because their own nominators withdrew them, not because FDA reversed its safety assessment), an advisory committee is now reported to have recommended six of them for formal compounding eligibility, and the executive branch is actively reviewing a mechanism that could open limited, conditional access.
One structural wrinkle worth noting: FDA stopped sorting newly-nominated bulk substances into the Category 1/2/3 system as of January 7, 2025, moving new nominations directly toward 503A Bulks List consideration instead [8]. The peptides discussed in this article were nominated and categorized before that change, so their existing Category 1/2 designations continue to apply under the prior framework until FDA takes further action — this doesn't change anything stated above, but it's a detail worth knowing if you see the category system itself described as discontinued.
What the formal rules still say: the 503A Bulks List itself, codified at 21 CFR 216.23, has not been amended to add any of these substances. No proposed rule covering them has published in the Federal Register. No peptide discussed in this article that lacks an FDA-approved product has gained one. And the research-use-only commercial channel — where most consumer-facing peptide sellers operate — sits entirely outside the 503A compounding framework; 2026's enforcement trend there has moved toward more scrutiny, not less.
For the separate question of which specific peptides already have FDA-approved finished products (as opposed to compounding eligibility), see FDA-Approved Peptides: The 2026 Guide.
Regulatory Categories, Precisely — Active Ingredient vs. Finished Product vs. Compounded Copy
It's easy to conflate “this ingredient is in an approved drug” with “this product is approved,” and the distinction matters for different peptides in different ways:
FDA-approved finished drug product. A specific formulation, dose, indication, and label that completed a New Drug Application review. Semaglutide and tirzepatide are active ingredients in several FDA-approved products (semaglutide in Ozempic and Wegovy; tirzepatide in Mounjaro and Zepbound). Those specific, approved products are not the subject of this article.
Compounded formulation of an approved ingredient. A pharmacy or outsourcing facility preparing its own version of a drug containing the same active ingredient as an approved product. This is legally distinct from the approved product itself, and compounding it is permitted only under specific conditions — including, historically, during a declared drug shortage. FDA's temporary shortage-related enforcement discretion for compounded tirzepatide ended March 5, 2025, and for compounded semaglutide ended April 24, 2025, per FDA's own September 2026 warning letter to Empower Pharmacy. After those dates, continuing to compound those ingredients in high volume — without an individualized, patient-specific basis — is the central finding in that letter. The letter specifically targets combination products (tirzepatide paired with niacinamide; semaglutide paired with cyanocobalamin) that FDA describes as copies of the approved products with an added ingredient, reportedly the first time FDA has applied a “pretextual compounding” theory to GLP-1 coformulations specifically.
Unapproved substance with no FDA-approved product at all. BPC-157, TB-500, MOTS-C, KPV, Epitalon, Semax, and Emideltide fall here. No finished drug product containing any of them has been approved, for any indication, by FDA. This is a different, and in some ways simpler, category than the GLP-1 situation above: there is no approved product to compare a compounded version against.
Research-use-only (RUO) material. Sold explicitly for laboratory and analytical use, not for human or animal administration. RUO labeling describes an intended use; it does not, on its own, establish that a product is lawfully marketed. FDA has rejected RUO labeling as a defense where a seller's broader marketing — bacteriostatic water, dosing calculators, reconstitution guides — indicates an intended human use.
503A and 503B Compounding: Two Different Legal Tests
Under Section 503A, a state-licensed pharmacy may compound a drug from a bulk substance only if that substance is a component of an FDA-approved drug, complies with an applicable USP or NF monograph, or appears on the formal 503A Bulks List. None of the seven peptides PCAC reviewed in July satisfies the first two routes on its own — which is why Bulks List inclusion was the specific question before the committee.
Section 503B covers FDA-registered outsourcing facilities operating under CGMP requirements, with its own separate bulks list and its own eligibility test. A substance's 503A status does not determine its 503B status, or the reverse. Whether a specific substance, in a specific form, for a specific route of administration, qualifies under either section is a substance-specific legal question — one this article describes in general terms but does not resolve for any individual product or practice.
Adding a substance to the formal 503A Bulks List requires notice-and-comment rulemaking: a proposed rule, a public comment period, review of the comments received, then a final rule. No statutory deadline forces this process. FDA's most comparable precedent — a 2016 proposed rule covering ten other bulk substances — took until February 2019 to finalize.
How FDA Documents and Statements Differ in Legal Weight
Not every FDA-adjacent document carries the same force, and confusing them is the single biggest source of “the FDA said X” errors in peptide coverage:
- Statutes and final rules (like the 503A Bulks List itself) are legally binding.
- Guidance documents describe FDA's current, generally non-binding thinking on how it intends to apply the law — they shape enforcement priorities but don't themselves carry the force of a rule.
- Warning letters state FDA's view that a specific, named firm is violating the law. They are not new rules and don't bind anyone other than that firm, though they signal how FDA reads existing requirements.
- Advisory committee recommendations (like PCAC's July vote) are non-binding input FDA is free to accept, reject, or modify.
- Enforcement discretion is FDA stating an intent not to pursue certain enforcement actions under specified conditions — it does not change the underlying law and can be narrowed or withdrawn without formal rulemaking.
- Public statements by officials (a podcast interview, a press quote) carry no legal force of any kind, however influential they are on policy direction.
What the 2026 Developments Mean in Practice
For compounding pharmacies and prescribers, none of the six PCAC-recommended peptides may currently be lawfully compounded under 503A on the strength of that recommendation alone. If the October 14 interim policy is adopted roughly as reported, it would most likely function as enforcement discretion — FDA stating it does not intend to pursue certain 503A pharmacies compounding under specified conditions — rather than formal authorization, and it could be withdrawn without a public comment process.
For laboratories and researchers buying RUO material, none of the 503A review changes their position, because RUO sale was never part of what PCAC reviewed. What has changed is FDA's enforcement posture: its 2026 warning letters show the agency treating a seller's full product lineup — not just the RUO label on one item — as evidence of intended use.
For compounding pharmacies working with GLP-1 ingredients specifically, the Empower Pharmacy letter is a useful, concrete example of where the current legal line sits: compounding an approved ingredient is permitted only under defined conditions, and high-volume production without individualized patient determinations is exactly what FDA flagged.
What None of This Establishes
A Category 2 withdrawal doesn't mean a substance is safe or compounding-eligible — it just means its own nominator walked away from the nomination. A PCAC recommendation doesn't bind FDA, which is on record taking the opposite position in this same review and isn't required to follow its own advisory committee either way. An OMB submission under interagency review has no legal deadline and no guaranteed outcome — the reginfo.gov record for this one currently shows only that a draft is pending. And RUO labeling is a claimed intended use, not a legal clearance — one FDA has explicitly looked behind before when a seller's broader marketing suggested otherwise.
How to Verify a Claim Like This Yourself
- Go to FDA's own 503A bulk drug substances page and its Category 2 safety-risk page; both display a “content current as of” date, which tells you how recent the page is — not, by itself, whether a specific claim on it is still accurate or has been superseded by a newer action elsewhere.
- Identify the specific legal mechanism involved — a statute, a final rule, a guidance document, a warning letter, an advisory vote, or a public statement — since each carries different weight.
- For a regulatory-review record like the October 2026 interim policy, check reginfo.gov directly by RIN rather than trusting a RIN quoted secondhand; RINs are agency- and rule-specific, and a mismatched one is easy to miss unless you check the source.
- Check whether a claim names the exact chemical form (free base vs. acetate), route of administration, and legal pathway (503A vs. 503B) — a status claim missing these is usually incomplete.
- Where a claim traces to litigation, enforcement, or a specific company, read that company's own posted warning letter or court filing rather than a summary of it.
Quick Answers to Common Questions
Did the FDA approve BPC-157, TB-500, or the other PCAC-reviewed peptides in 2026? No. PCAC is reported to have recommended six of seven peptide groups for the 503A Bulks List, but a recommendation is not an approval or a rule change, and no proposed rule covering these peptides had published as of October 20, 2026.
Did semaglutide and tirzepatide get a different kind of scrutiny than BPC-157 and the others? Yes, and the distinction matters. Semaglutide and tirzepatide are active ingredients in FDA-approved products; FDA's September 2026 action concerned compounded, unapproved combination versions of those ingredients made after shortage-related compounding allowances had ended. BPC-157 and the PCAC-reviewed peptides have no FDA-approved product in any form, which is a different legal question entirely.
Is it true that peptides moved from “Category 2” to “Category 1” in 2026? No FDA document supports that framing. A group of nominations was withdrawn by the people who filed them in April 2026, moving those substances to a separate “nominated but withdrawn” table — outside the Category 1 enforcement policy, not inside it.
What is the October 14, 2026 “interim access policy,” exactly? A draft policy (RIN 0910-ZD94) HHS and FDA submitted to the White House Office of Management and Budget for review. As of this cutoff it is at the “Notice” stage of Pending EO 12866 Regulatory Review, has no legal deadline, and has not been published.
Does Research Use Only (RUO) labeling make a peptide legal to sell or use? No. RUO labeling states an intended use; it doesn't establish legality on its own. FDA's August 2026 warning letter to TXP Innovations LLC dba Tex Peptides rejected that labeling where bacteriostatic water and dosing tools indicated an intended human use.
What is the difference between 503A and 503B compounding? Section 503A covers state-licensed pharmacies compounding for an identified patient; Section 503B covers FDA-registered outsourcing facilities under CGMP. The two sections apply different eligibility tests and maintain separate bulk-substance lists; a substance's status under one doesn't determine its status under the other.
Conclusion
The accurate summary of 2026, narrowed to what's actually on the record: a defined group of peptides left a safety-risk list because their own nominators withdrew them, not because FDA found them safe. An advisory committee then recommended six of them for formal compounding eligibility, over FDA staff's own prior position, reportedly on votes cast entirely by members with ties to the industry. The federal government is now reviewing a draft policy, under a specific, checkable OMB docket number, that could eventually open a narrow, conditional compounding channel.
Separately, and on a different track entirely, FDA's 2026 enforcement actions — against an RUO seller and against a compounding pharmacy's GLP-1 combination products — show the agency actively policing both ends of the market in the meantime. None of this is a drug approval, a finalized rule, or a safety determination, and none of it extends to RUO commercial sale. Check FDA's and OMB's own primary pages directly, by date and by RIN, before relying on any secondhand summary of this fast-moving area — including this one.
This article is for general educational information only. It is not legal, medical, or regulatory advice, and it does not establish or imply FDA approval, endorsement, or authorization of any Certified Aminos product. Certified Aminos products are sold strictly for research, laboratory, and analytical use and are not intended for human or veterinary administration, diagnosis, treatment, cure, or prevention of any disease. Consult qualified legal or regulatory counsel for guidance specific to your circumstances.
For general background, see our Legality & Compliance FAQ, FDA-Approved Peptides: The 2026 Guide, Thymosin Alpha-1 research guide, and how GLP-1 peptides are engineered for a weekly half-life.
